Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor
prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

Recent discovery of mutations in the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR) gene in lung adenocarcinoma greatly stimulated biomarker research on …

Lung cancer is the leading cause of cancer-related death in men and women in the United
States, accounting for approximately 28% of total cancer deaths in 2010 despite comprising …

Cancer therapies targeting epidermal growth factor receptor (EGFR), such as small-
molecule kinase inhibitors and monoclonal antibodies, have been developed as standard …

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the
detection of actionable mutations, which has revolutionized the treatment paradigm in this …

Introduction In IPASS (IRESSA Pan-Asia Study), clinically selected patients with pulmonary
adenocarcinoma received first-line gefitinib or carboplatin/paclitaxel. This preplanned …

Purpose: The epidermal growth factor receptor (EGFR) and its downstream factors KRAS
and BRAF are mutated with different frequencies in non–small cell lung cancer and …

Abstract Purpose: African Americans have higher incidence and poorer response to lung
cancer treatment compared with Caucasians. However, the underlying molecular …

Mutation in the epidermal growth factor receptor (EGFR) is frequently seen in non‐small cell
lung cancers (NSCLCs), especially in Asian females with adenocarcinoma. The frequency of …